Hills Bank & Trust Co. boosted its position in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 4.5% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,495 shares of the medical equipment provider’s stock after buying an additional 972 shares during the quarter. Hills Bank & Trust Co.’s holdings in Zimmer Biomet were worth $2,872,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also recently added to or reduced their stakes in the company. Town & Country Bank & Trust CO dba First Bankers Trust CO boosted its holdings in shares of Zimmer Biomet by 100.0% in the fourth quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO now owns 3,306 shares of the medical equipment provider’s stock worth $343,000 after acquiring an additional 1,653 shares during the period. Dubuque Bank & Trust Co. bought a new position in shares of Zimmer Biomet in the first quarter worth $84,000. LaFleur & Godfrey LLC boosted its holdings in shares of Zimmer Biomet by 8.8% in the first quarter. LaFleur & Godfrey LLC now owns 36,320 shares of the medical equipment provider’s stock worth $4,638,000 after acquiring an additional 2,935 shares during the period. Aries Wealth Management bought a new position in shares of Zimmer Biomet in the first quarter worth $206,000. Finally, Legacy Financial Advisors Inc. boosted its holdings in shares of Zimmer Biomet by 176.4% in the fourth quarter. Legacy Financial Advisors Inc. now owns 351 shares of the medical equipment provider’s stock worth $36,000 after acquiring an additional 224 shares during the period. 89.82% of the stock is owned by institutional investors and hedge funds.
NYSE:ZBH opened at $119.69 on Thursday. The firm has a market cap of $24.49 billion, a P/E ratio of 15.67, a price-to-earnings-growth ratio of 2.25 and a beta of 1.23. Zimmer Biomet Holdings Inc has a 52-week low of $96.99 and a 52-week high of $134.55. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.83 and a quick ratio of 0.90.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.80%. The ex-dividend date of this dividend is Thursday, March 28th. Zimmer Biomet’s dividend payout ratio is 12.57%.
In other news, Director Betsy J. Bernard purchased 4,250 shares of the company’s stock in a transaction on Wednesday, February 6th. The stock was purchased at an average price of $117.41 per share, with a total value of $498,992.50. Following the completion of the purchase, the director now directly owns 2,000 shares in the company, valued at approximately $234,820. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Bryan C. Hanson purchased 2,100 shares of the company’s stock in a transaction on Thursday, February 7th. The shares were purchased at an average cost of $119.02 per share, with a total value of $249,942.00. Following the purchase, the insider now owns 30,615 shares of the company’s stock, valued at $3,643,797.30. The disclosure for this purchase can be found here. Insiders have purchased 12,860 shares of company stock valued at $1,548,994 in the last three months. 0.72% of the stock is owned by corporate insiders.
A number of equities analysts have recently commented on ZBH shares. Zacks Investment Research lowered Zimmer Biomet from a “hold” rating to a “sell” rating in a report on Saturday, April 13th. Citigroup raised Zimmer Biomet from a “neutral” rating to a “buy” rating and raised their price target for the stock from $122.00 to $127.00 in a report on Wednesday, January 2nd. Evercore ISI raised Zimmer Biomet from an “in-line” rating to an “outperform” rating and set a $145.00 price target for the company in a report on Monday, April 8th. JPMorgan Chase & Co. lowered Zimmer Biomet from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $140.00 to $118.00 in a report on Wednesday, December 19th. Finally, Stifel Nicolaus cut their price target on Zimmer Biomet from $150.00 to $135.00 and set a “buy” rating for the company in a report on Tuesday, January 22nd. Four equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $129.95.
TRADEMARK VIOLATION NOTICE: “Hills Bank & Trust Co. Purchases 972 Shares of Zimmer Biomet Holdings Inc (ZBH)” was posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.com-unik.info/2019/04/18/hills-bank-trust-co-purchases-972-shares-of-zimmer-biomet-holdings-inc-zbh.html.
Zimmer Biomet Profile
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.